Zacks Research Issues Negative Outlook for Amgen Earnings

Amgen Inc. (NASDAQ:AMGN - Free Report) - Research analysts at Zacks Research dropped their Q2 2025 earnings estimates for shares of Amgen in a research report issued on Thursday, May 22nd. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $5.20 per share for the quarter, down from their prior estimate of $5.22. The consensus estimate for Amgen's current full-year earnings is $20.62 per share. Zacks Research also issued estimates for Amgen's Q3 2025 earnings at $5.32 EPS, Q4 2025 earnings at $5.24 EPS, Q1 2026 earnings at $4.60 EPS, Q2 2026 earnings at $5.24 EPS, Q3 2026 earnings at $5.29 EPS, Q4 2026 earnings at $5.34 EPS and FY2026 earnings at $20.48 EPS.

Several other equities analysts have also weighed in on the stock. Johnson Rice set a $294.00 price target on shares of Amgen in a research report on Wednesday, March 5th. Royal Bank of Canada cut their price objective on shares of Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. UBS Group reaffirmed a "neutral" rating and issued a $315.00 price objective (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Bank of America raised their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Finally, Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a report on Friday, May 2nd. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $309.22.

Amgen Stock Up 1.5%

Shares of AMGN stock traded up $4.27 on Monday, hitting $282.67. The stock had a trading volume of 1,671,836 shares, compared to its average volume of 2,797,000. The business has a 50 day moving average of $284.48 and a 200 day moving average of $285.76. The stock has a market cap of $151.99 billion, a price-to-earnings ratio of 37.40, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the prior year, the company posted $3.96 earnings per share. The business's revenue was up 9.4% on a year-over-year basis.

Institutional Trading of Amgen

Several institutional investors have recently added to or reduced their stakes in the business. Centricity Wealth Management LLC bought a new position in shares of Amgen during the fourth quarter valued at about $25,000. Wealth Preservation Advisors LLC bought a new position in shares of Amgen during the first quarter valued at about $25,000. Pinney & Scofield Inc. bought a new position in shares of Amgen during the fourth quarter valued at about $26,000. First Pacific Financial raised its stake in shares of Amgen by 304.5% during the first quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after acquiring an additional 67 shares during the last quarter. Finally, Ritter Daniher Financial Advisory LLC DE raised its stake in shares of Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.37%. Amgen's dividend payout ratio (DPR) is presently 86.86%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.